Neurocrine Biosciences (NASDAQ:NBIX – Get Rating) had its target price decreased by Mizuho from $116.00 to $111.00 in a research note released on Thursday, The Fly reports. Other research analysts also recently issued reports about the company. Evercore ISI upgraded Neurocrine Biosciences from an in-line rating to an outperform rating and set a $130.00 target […]
Shell Asset Management Co. cut its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) by 15.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 4,533 shares of the company’s stock after selling 811 shares during the quarter. Shell Asset Management Co.’s […]
Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) – Equities researchers at Cantor Fitzgerald issued their FY2023 earnings per share estimates for Neurocrine Biosciences in a report released on Thursday, April 27th. Cantor Fitzgerald analyst C. Duncan forecasts that the company will post earnings per share of $2.55 for the year. Cantor Fitzgerald has a “Overweight” […]
Harvest Fund Management Co. Ltd acquired a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 1,096 shares of the company’s stock, valued at approximately $131,000. A number of other […]
Neurocrine Biosciences (NASDAQ:NBIX – Get Rating) had its target price reduced by Citigroup from $131.00 to $127.00 in a research report report published on Wednesday, The Fly reports. Citigroup currently has a buy rating on the stock. Several other research firms also recently commented on NBIX. Canaccord Genuity Group upgraded shares of Neurocrine Biosciences from […]